Big Pharma's Bargain Bin: Why Traditional Drug Giants Are Trading at Record Discounts to the Market

A tale of two pharmas is playing out in the stock market. While Eli Lilly and Novo Nordisk command premium valuations on the strength of their GLP-1 obesity drugs, the rest of the pharmaceutical industry has been left behind, trading at historically depressed multiples that have some investors salivating and others running for cover.

The Numbers Behind the Discount

Pfizer, once the poster child for pandemic-era pharmaceutical success, currently trades at just 8.3 times forward earnings—a fraction of the broader S&P 500's multiple. The company's stock sits near $26, well off its pandemic highs, with analysts issuing lukewarm "hold" ratings and modest 12-month price targets that imply barely 6% upside.

Merck presents a similar picture. Despite owning Keytruda, one of the most successful cancer drugs in history, the company trades at a discount to the market even as it prepares defensive measures ahead of Keytruda's 2028 patent cliff. Johnson & Johnson, AbbVie, and Bristol-Myers Squibb all share the same fate—solid businesses trading as if they're in terminal decline.

The contrast with the obesity drug leaders is stark. Eli Lilly, buoyed by Mounjaro and Zepbound sales, trades at over 50 times forward earnings. Novo Nordisk commands a similar premium for Ozempic and Wegovy. The market has essentially declared that these two companies own the future of pharma, while everyone else is merely managing decline.

What's Weighing on Traditional Pharma

Several factors have combined to pressure traditional pharmaceutical valuations:

Medicare Drug Price Negotiations: The Centers for Medicare & Medicaid Services finalized 38% to 79% discounts on ten high-cost drugs effective January 2026. For companies with significant Medicare exposure, this represents a meaningful hit to revenue that wasn't fully priced in when negotiations began.

Patent Cliffs: The industry faces a wave of patent expirations over the next five years. Keytruda alone represents tens of billions in annual revenue that Merck must replace or see evaporate. Bristol-Myers Squibb faces similar pressures with Opdivo and Eliquis.

The GLP-1 Shadow: Beyond their direct competition in obesity and diabetes, GLP-1 drugs are showing promise in cardiovascular disease, kidney disease, and other conditions—potentially displacing treatments from traditional pharma companies.

"Pfizer Inc and Merck & Co Inc aren't exciting stocks anymore—and after a bruising reset, that's starting to look intentional. These companies are being valued like utilities, not growth stocks."

— Healthcare sector analyst

The Bull Case for Value

JPMorgan expects large-cap biopharma stocks to outperform in 2026, seeing a combination of lower policy risk, solid fundamentals, and still-low valuations as potential catalysts. The argument is straightforward: at current prices, you're essentially getting free options on pipeline drugs while collecting dividends that increasingly look attractive relative to bond yields.

Pfizer's $10 billion acquisition of Metsera signals the company's determination to gain a foothold in the obesity market, potentially transforming its growth profile. AbbVie has successfully navigated its Humira patent cliff, with Skyrizi and Rinvoq now generating revenue that exceeds Humira at its peak. Merck's subcutaneous Keytruda formulation, approved in September, should help defend the franchise longer than bears expect.

Perhaps most importantly, healthcare spending in America isn't slowing down. The Centers for Medicare and Medicaid Services estimates U.S. healthcare spending will grow 5.8% annually through 2033. Someone has to capture that growth, and it won't all go to two obesity drug companies.

The Bear Case for Value Traps

Skeptics argue that the market is efficiently pricing in real structural challenges. Patent cliffs aren't hypothetical—they're calendared events that will definitively reduce revenue. Pipeline drugs have historically high failure rates, and even successful launches rarely replace flagship products dollar-for-dollar.

More troubling, the obesity drug revolution may prove more disruptive than optimists acknowledge. If GLP-1s reduce cardiovascular events, they reduce the need for heart medications. If they prevent diabetes progression, they prevent the need for diabetes drugs. The success of Lilly and Novo may literally come at the expense of traditional pharma's existing revenue streams.

What Pfizer's Earnings Could Reveal

Pfizer reports earnings on February 3, providing investors with fresh data on the company's turnaround progress. Analysts expect earnings of $0.57 per share on revenue of approximately $16.85 billion. The real focus will be on commentary regarding the Metsera acquisition timeline, progress on non-COVID pipeline programs, and any updates on cost-cutting initiatives.

For investors trying to decide whether big pharma represents deep value or a value trap, Pfizer's report could prove illuminating. A company that demonstrates credible paths to growth—whether through obesity drugs, oncology, or other therapeutic areas—may help lift the entire sector from its valuation doldrums.

Until then, traditional pharma remains the market's bargain bin: full of recognizable names at discounted prices, but requiring patience and conviction to shop there successfully.